Dupixent® (dupilumab) approved in the u.s. as the first-ever biologic medicine for patients with copd

Dupixent is indicated for the approximately 300,000 adults in the u.s. with inadequately controlled chronic obstructive pulmonary disease (copd) and an eosinophilic phenotype

REGN Ratings Summary

REGN Quant Ranking